Table 1.
Patient demographics and baseline characteristics
| Characteristic | N = 65 |
|---|---|
| Race, n (%) | |
| Asian | 65 (100.0) |
| Sex, n (%) | |
| Male | 45 (69.2) |
| Female | 20 (30.8) |
| Age, y | |
| Median | 68.0 |
| Range | 28-85 |
| Mean ± SD | 66.4 ± 11.1 |
| <65, n (%) | 25 (38.5) |
| ≥65, n (%) | 40 (61.5) |
| ECOG performance status, n (%) | |
| 0 | 36 (55.4) |
| 1 | 25 (38.5) |
| 2 | 4 (6.2) |
| PTCL subtype by central review, n (%) | |
| PTCL-NOS | 43 (66.2) |
| AITL | 17 (26.2) |
| ALCL-ALK positive | 0 |
| ALCL-ALK negative | 3 (4.6) |
| Clinical stage by Ann Arbor classification, n (%) | |
| Stage I | 2 (3.1) |
| Stage II | 5 (7.7) |
| Stage III | 30 (46.2) |
| Stage IV | 28 (43.1) |
| Number of previous chemotherapy regimens | |
| Median | 2.0 |
| Range | 1-11 |
| Mean ± SD | 2.4 ± 1.8 |
| Relapsed/refractory status, n (%) | |
| Relapsed | 39 (60.0) |
| Refractory | 21 (32.3) |
| Unknown/unable to assess | 5 (7.7) |
| Previous hematopoietic stem cell transplant, n (%) | |
| No | 57 (87.7) |
| Yes | 8 (12.3) |
| Previous radiation therapy, n (%) | |
| No | 58 (89.2) |
| Yes | 7 (10.8) |
ECOG, Eastern Cooperative Oncology Group; SD, standard deviation.